雷贝拉唑联合瑞巴派特治疗活动性胃溃疡的疗效及其对炎性反应的影响  

Efficacy of Rabeprazole Combined with Rebamipide in the Treatment of Active Gastric Ulcer and Its Effects on Inflammatory Response

作　　者：王文斌[1] 蒋丰娟 乔根芳 WANG Wenbin;JIANG Fengjuan;QIAO Genfang(Department of Gastroenterology,Yangzhou Jiangdu People´s Hospital,Yangzhou,Jiangsu Province,225200 China)

机构地区：[1]扬州市江都人民医院消化内科,江苏扬州225200

出　　处：《世界复合医学》2022年第12期185-189,共5页World Journal of Complex Medicine

基　　金：扬州市江都人民医院院内科研基金项目(YNKT201903)。

摘　　要：目的 探讨对活动性胃溃疡者予雷贝拉唑联合瑞巴派特治疗的临床疗效及对减轻炎性反应的作用。方法 选取2016年1月—2021年12月扬州市江都人民医院收治的活动性胃溃疡者86例为研究对象,根据不同治疗方案将患者分为两组,对照组(n=42)予雷贝拉唑治疗,观察组(n=44)在对照组基础上联合瑞巴派特治疗,比较两组临床疗效、治疗前后组织学愈合质量评分以及白介素(IL)-17、IL-25水平。结果 观察组总有效率较对照组高(95.45%vs 78.57%),差异有统计学意义(P<0.05)。观察组治疗后炎症细胞浸润、胃黏膜厚度、中性黏液含量评分分别为(1.14±0.25)分、(0.54±0.17)分、(0.75±0.22)分,低于对照组的(1.32±0.31)分、(1.03±0.26)分、(1.12±0.24)分,差异有统计学意义(P<0.05)。观察组治疗后IL-17、IL-25水平分别为(148.55±20.13)、(732.25±81.21)pg/mL,均低于对照组的(173.21±21.70)、(827.38±96.65)pg/mL,差异有统计学意义(P<0.05)。结论 对活动性胃溃疡患者予雷贝拉唑联合瑞巴派特治疗可提高临床疗效,有利于促进溃疡愈合,并可减轻机体炎症反应。Objective To investigate the clinical efficacy of rabeprazole combined with rebamipide in patients with active gastric ulcer and its effect on reducing the inflammatory response.Methods 86 patients with active gastric ulcer admitted to Yangzhou Jiangdu People´s Hospital from January 2016 to December 2021 were selected as the study subjets,and the patients were divided into two groups according to different treatment regimens.The control group(n=42)was treated with rabeprazole and the observation group(n=44)was treated with combination of rebamipide on the basis of control group.The clinical efficacy,histological healing quality,IL-17 and IL-25 levels before and after treatment of the two groups was compared.Results The total effective rate in the observation group was higher than that in the control group(95.45%vs 78.57%),the difference was statistically significant(P<0.05).The post-treatment inflammatory cell infiltration,gastric mucosal thickness,and neutral mucus content scores in the observation group were(1.14±0.25)points,(0.54±0.17)points,and(0.75±0.22)points,respectively,which were lower than those in the control group(1.32±0.31)points,(1.03±0.26)points,and(1.12±0.24)points,the difference was statistically significant(P<0.05).The IL-17 and IL-25 levels in the observation group were(148.55±20.13)pg/mL and(732.25±81.21)pg/mL after treatment,which were lower than those in the control group(173.21±21.70)pg/mL and(827.38±96.65)pg/mL,respectively,the difference was statistically significant(P<0.05).Conclusion In patients with active gastric ulcer,treatment with rabeprazole combined with rebamipide improves clinical efficacy, promotes ulcer healing, and reduces the inflammatory response of the body.

关 键 词：雷贝拉唑 瑞巴派特 活动性胃溃疡 炎性反应 组织愈合 

分 类 号：R573[医药卫生—消化系统]